Comparison of interteron α2β monotherapy with the combination of thymosin α1 and interferon α2b in the treatment of anti-HBe-postive chronic hepatitis B in turkey
✍ Scribed by Saruc, Murat; Yuceya, Hakan; Kucukmetin, Nurten; Demir, Mehmet A.; Kandiloglu, Ali R.
- Book ID
- 124147259
- Publisher
- Elsevier Science
- Year
- 2001
- Tongue
- English
- Weight
- 190 KB
- Volume
- 120
- Category
- Article
- ISSN
- 0016-5085
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Hepatitis B e antibody (HbeAb) and hepatitis B virus (HBV) DNA positive chronic hepatitis is a clinical entity, distinct from classical hepatitis B e antigen (HbeAg) positive chronic hepatitis B. Our aim was to evaluate the long-term therapeutic efficacy of the combination of interferon alpha-2b and
## Treatment of chronic hepatitis C with Interferon (IFN) ␣2b monotherapy results in 10% to 15% sustained virological response (SVR). Combining IFN with ribavirin increases this response. In this analysis, using the Markov model, 6 treatment strategies for chronic hepatitis C (previously untreated